Advances in the Immunobiology and Treatment of Inflammatory Myopathies

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2007 Aug 11

PMID 17688838

Citations 3

Authors

Marinos C Dalakas

Affiliations

Soon will be listed here.

Abstract

The clinical spectrum and immunopathogenesis of inflammatory myopathies are summarized with an update on possible triggering factors, cell degeneration, and emerging new therapies.

Citing Articles

Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation.

Vitadello M, Doria A, Tarricone E, Ghirardello A, Gorza L Arthritis Res Ther. 2010; 12(2):R52.

PMID: 20334640 PMC: 2888201. DOI: 10.1186/ar2963.

Clinical applications of intravenous immunoglobulins in neurology.

Hughes R, Dalakas M, Cornblath D, Latov N, Weksler M, Relkin N Clin Exp Immunol. 2009; 158 Suppl 1:34-42.

PMID: 19883422 PMC: 2801030. DOI: 10.1111/j.1365-2249.2009.04025.x.

In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized.

Terracciano C, Nogalska A, Engel W, Wojcik S, Askanas V Free Radic Biol Med. 2008; 45(6):773-9.

PMID: 18601999 PMC: 2579266. DOI: 10.1016/j.freeradbiomed.2008.05.030.

References

Emslie-Smith A, Arahata K, Engel A . Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989; 20(3):224-31. DOI: 10.1016/0046-8177(89)90128-7. View

Ozden S, Cochet M, Mikol J, Teixeira A, Gessain A, Pique C . Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol. 2004; 78(19):10320-7. PMC: 516372. DOI: 10.1128/JVI.78.19.10320-10327.2004. View

Vattemi G, Engel W, McFerrin J, Askanas V . Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol. 2003; 164(1):1-7. PMC: 1602240. DOI: 10.1016/S0002-9440(10)63089-1. View

Dimitri D, Benveniste O, Dubourg O, Maisonobe T, Eymard B, Amoura Z . Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain. 2006; 129(Pt 4):986-95. DOI: 10.1093/brain/awl020. View

Illa I, Dalakas M . Polymyositis in patients infected with human T-cell leukemia virus type I: the role of the virus in the cause of the disease. Ann Neurol. 1994; 36(4):643-9. DOI: 10.1002/ana.410360414. View

Raju R, Dalakas M . Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005; 128(Pt 8):1887-96. DOI: 10.1093/brain/awh518. View

Dalakas M . Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991; 325(21):1487-98. DOI: 10.1056/NEJM199111213252107. View

Dalakas M, Pezeshkpour G, Gravell M, Sever J . Polymyositis associated with AIDS retrovirus. JAMA. 1986; 256(17):2381-3. View

Greenberg S, Pinkus G, Amato A, Pinkus J . Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve. 2006; 35(1):17-23. DOI: 10.1002/mus.20649. View

10.

Ferrer I, Carmona M, Blanco R, Moreno D, Torrejon-Escribano B, Olive M . Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis. Brain Pathol. 2005; 15(2):101-8. PMC: 8095801. DOI: 10.1111/j.1750-3639.2005.tb00504.x. View

11.

Dalakas M, Hohlfeld R . Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-82. DOI: 10.1016/S0140-6736(03)14368-1. View

12.

Nishio J, Suzuki M, Miyasaka N, Kohsaka H . Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol. 2001; 167(7):4051-8. DOI: 10.4049/jimmunol.167.7.4051. View

13.

Murata K, Dalakas M . Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol. 1999; 155(2):453-60. PMC: 1866856. DOI: 10.1016/s0002-9440(10)65141-3. View

14.

Dalakas M . Immunopathogenesis of inflammatory myopathies. Ann Neurol. 1995; 37 Suppl 1:S74-86. DOI: 10.1002/ana.410370709. View

15.

Fratta P, Engel W, McFerrin J, Davies K, Lin S, Askanas V . Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol. 2005; 167(2):517-26. PMC: 1603556. DOI: 10.1016/s0002-9440(10)62994-x. View

16.

Illa I, Gallardo E, Gimeno R, Serrano C, Ferrer I, Juarez C . Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies. Am J Pathol. 1997; 151(1):81-8. PMC: 1857938. View

17.

Brunn A, Schroder R, Deckert M . The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex. Acta Neuropathol. 2006; 112(3):325-32. DOI: 10.1007/s00401-006-0113-5. View

18.

Dalakas M . B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther. 2006; 112(1):57-70. DOI: 10.1016/j.pharmthera.2006.03.005. View

19.

Dalakas M . Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology. 2006; 66(2 Suppl 1):S33-8. DOI: 10.1212/01.wnl.0000192129.65677.87. View

20.

Ferrer I, Martin B, Castano J, Lucas J, Moreno D, Olive M . Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol. 2004; 63(5):484-98. DOI: 10.1093/jnen/63.5.484. View